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Acute leukemia is a disorder of the hematopoietic system characterized by the expansion of a clonal pop-
ulation of cells blocked fromdifferentiating intomature cells. Recent studies have shown that chalcones and
their derivatives induce apoptosis in different cell lines. Since new compounds with biological activity are
needed, the aim of this study was to evaluate the cytotoxic effect of three synthetic chalcones, derived from
1-naphthaldehyde and 2-naphthaldehyde, on human acute myeloid leukemia K562 cells and on human
acute lymphoblastic leukemia Jurkat cells. Based on the results, the most cytotoxic compound (A1) was
chosen for further analysis in six human acute leukemia cells and in a human colon adenocarcinoma cell line
(HT-29). Chalcone A1 signiﬁcantly reduced the cell viability of K562, Jurkat, Kasumi, U937, CEM and NB4
cells in a concentration and time-dependent manner when compared with the control group (IC50 values
betweenw1.5 mM and 40 mM). It was also cytotoxic to HL-29 cells. To further examine its effect on normal
cells, peripheral blood lymphocytes collected from healthy volunteers were incubated with the compound.
It has also been incubated with human ﬁbroblasts cultured from bone marrow (JMA). Chalcone A1 is non-
cytotoxic to PBL cells and to JMAcells.A1 caused signiﬁcant cell cycle arrest in all phases according to the cell
line, and increased the proportion of cells in the sub G0/G1 phase. To evaluate whether this chalcone
induced cell death via an apoptotic or necrotic pathway, cell morphology was examined using ﬂuorescence
microscopy. Cells treated with A1 at IC50 demonstrated the morphological characteristic of apoptosis, such
as chromatin condensation and formation of apoptotic bodies. Apoptosis was conﬁrmed by externalization
of phosphatidylserine, which was detected by the Annexin V-FITC method, and by DNA fragmentation. The
results suggest that chalcone A1 has potential as a new lead compound for cancer therapy.
 2012 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Acute leukemia is a disorder of the hematopoietic system charac-
terized by the expansion of a clonal population of cells that is blocked
from differentiating into mature cells, which may occur in bone
marrow or in lymphoid tissues [1,2]. The leukemic clone may arise at
different stages of differentiation of the lymphoid and myeloid
precursors,which characterizes this type of cancer as a heterogeneous
disease in biological and morphological terms [3e5].Santa Catarina, Centro de
, Campus Trindade, Zip Code
8146; fax: þ55 48 37219542.
ioral).
nder the Elsevier OA license.Despite being themost effective treatment for leukemia, standard
chemotherapy is still associatedwith patient relapse, highmorbidity
and high mortality rates [6]. The killing of tumor cells by these
therapies is mediated primarily by induction of apoptosis, which
suggests that resistance of tumor cells to therapy can be caused by
a failure in the ability to initiate apoptosis [7]. Apoptosis is a term
introduced in 1972 to distinguish one type of programmed cell death
with characteristic morphology and highly regulated endogenous
mechanisms [8]. The homeostasis of normal cells is the result of
a balance between proliferation, differentiation and apoptosis
whereas malignant processes are characterized by the excessive
expansion of tumor cells due to failures in one or more of these
processes [9]. Therefore, treatment strategies with new antineo-
plastic drugs that have greater speciﬁcity in inducing apoptosis of
M.F. Maioral et al. / Biochimie 95 (2013) 866e874 867tumor cells are needed, not only to improve the cure rate but also the
patients’ quality of life [10]. In order to achieve this, understanding
the mechanisms of cell cycle regulation and apoptosis is critical in
relation to identifying new targets for antileukemic therapy.
Chalcones are naturally-occurring open-chain ﬂavonoids iso-
lated from some plants and include plant allelochemicals and insect
hormones and pheromones [11]. They are prepared by condensing
aryl ketones with aromatic aldehydes in the presence of suitable
condensing agents [12]. They undergo a variety of chemical reac-
tions and have been used in the synthesis of a variety of synthetic
heterocyclic compounds [13e15]. Several biological effects suggest
a potential pharmaceutical use of chalcones, such as antimicrobial
[16], anti-inﬂammatory [17,18], analgesic [19], antiviral [20] and
anticancer [13]. Studies have also shown that chalcones have
antiproliferative and cytotoxic effects [13,14,21], and may also
arrest the cell cycle in different tumor cell lines [22e25]. Several
studies have reported that chalcones can block the cell cycle in the
G2/M phase [25e28], while others show blocking in the G0/G1
phase [29,30]. However, the effect of chalcones and their deriva-
tives in the transduction of signals which control the cell cycle and
induce the apoptosis of cells are still controversial.
We have previously reported the cytotoxic effects of a series of
chalcones derived from 2-naphthaldehyde.We found that chalcone
(2E)-3-(2-naphthalenyl)-1-(30-methoxy-40-hydroxy-phenyl)-2-
propene-1-one showed a strong cytotoxic effect, with an IC50 value
of 54 mM being obtained in tests on mouse acute lymphoblastic
leukemia cells (L-1210). The mechanisms of apoptosis were inves-
tigated and it was found that this compound causes blocking of the
cell cycle in the G2/M phase and apoptosis via the mitochondrial
pathway. This ﬁndingwas explained by the decreased expression of
Bcl-2 and increased expression of Bax, which results in caspase-3
activation and cell death [25]. However, despite possessing the
pharmacological properties required for the development of an
antitumor drug, the IC50 value of 54 mM is prohibitively high.
In this context, three structural analogs of (2E)-3-(2-naphthalenyl)-
1-(30-methoxy-40-hydroxy-phenyl)-2-propene-1-one were prepared:
(2E)-1-(3,4,5-trimethoxy-phenyl)-3-(2-naphthyl)-2-propene-1-
one (C24), (2E)-1-(3,4,5-trimethoxy-phenyl)-3-(1-naphthyl)-2-
propene-1-one (A23) and (2E)-1-(2,5-dimethoxy-phenyl)-3-(1-
naphthyl)-2-propene-1-one (A1) (Fig. 1). These compounds
had been previously synthesized by our group [31], but no tests
had been carried out to identify possible cytotoxic effects on
leukemia cells.
The main purpose of this study was to assess the cytotoxic effect
of these three synthetic chalcones (C24, A23 and A1) on a human
acute myeloid leukemia cell line (K562) and a human acute
lymphoblastic leukemia cell line (Jurkat). Based on the results ob-
tained, we selected the most cytotoxic compound for further
analysis. Considering the different biological characteristics and
therapeutic responses of acute leukemia, we investigated the
effects of the most active chalcone in six different types and
subtypes of human leukemia cells (K562, Jurkat, U937, Kasumi, NB4
and CEM). In addition, we investigated the effect of this compound
on the cell cycle and on apoptosis induction, in order to clarify its
mechanism of action, seeking a potential lead compound in the
search for new antitumor agents.Fig. 1. Structures of chalco2. Materials and methods
2.1. Synthesis
The reagents used were obtained commercially from Sigmae
Aldrich and solvents from Vetec. The chalcones were prepared
by aldolic condensation using methanol as the solvent under basic
conditions (KOH 50% w/v) at room temperature for 24 h. Distilled
water and 10% hydrochloric acid were added to the reaction for
total precipitation of the compounds, which were then obtained by
vacuum ﬁltration and later recrystallized in dichloromethane and
hexane. The structures were identiﬁed by melting point, infrared
spectroscopy (IR), 1H and 13C nuclear magnetic resonance (NMR)
spectroscopy and elementary analysis, as previously described by
our group [31].2.2. Cell culture
Six human leukemia cell lines were used in this study: chronic
myeloid leukemia in blast crisis (K562), acute lymphoblastic
leukemia (Jurkat), monocyte-like histiocytic lymphoma (U937),
(8:21)-kit mutant model for acute myeloid leukemia (Kasumi),
acute promyelocytic leukemia (NB4) and T-cell leukemia (CEM). It
also has been used human colon adenocarcinoma cells (HT-29)
and human ﬁbroblasts cultured from bone marrow (JMA) as
a solid tumor model and as a control for actively proliferating
stable cells, respectively. Cells were cultured in Roswell Park
Memorial Institute Medium (RPMI) or Dulbecco’s Modiﬁed Eagle’s
Medium (DEMEM) (GIBCO, São Paulo, SP, Brazil) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml
penicillin, 100 mg/ml streptomycin and 10 mM HEPES under 5%
CO2 humidiﬁed atmosphere in75 cm2 ﬂasks. JMA cells were
cultured in Iscove’s Modiﬁed Dulbecco Medium (IMDM) (GIBCO,
São Paulo, SP, Brazil) supplemented with 20% FBS and 100 U/ml
penicillin and streptomycin. All these cell lines were purchased
from American Type Culture Collection (ATCC, Rockville, MD, USA)
or Rio de Janeiro Cell Bank (BCRJ, Rio de Janeiro, RJ, Brazil). Cell
viability counts were obtained using the Trypan blue exclusion
assay.2.3. Samples from healthy volunteers
This study was approved by the Medical Ethics Committee
238/03. Five non-smoking healthy volunteers who had never been
treated with any cancer drugs entered this study between August
2011 and September 2011 at the Polydoro Ernani de São Thiago
University Hospital (Florianópolis, Brazil). Blood samples were
collected and human peripheral blood lymphocytes were isolated
by the FicolleHypaque method [32]. Brieﬂy, after diluting blood
with PBS, lymphocytes were isolated by centrifugation over
a density gradient of FicolleHypaque (density ¼ 1.070 g/ml) for
30 min at 2000 rpm. Cells were washed with PBS twice and then
suspended in RPMI with 10% fetal bovine serum. The viability of the
isolated lymphocytes was measured by the Trypan blue exclusion
assay and found to be around 95%.nes C24, A23 and A1.
Fig. 2. Cytotoxicity of chalcones C24, A23 and A1 against acute leukemia cell lines. K562 (a) and Jurkat (b) cells (1  105 cells/well) were incubated with the three chalcones (1e
100 mM) for 24 h. The cell viability was monitored through MTT assay. Optical density of the control groups was taken as 100% of cell viability. Cell viability was checked at the
beginning of the experiment by Trypan blue exclusion. The results are the mean  SD of at least 3 independent experiments. *p < 0.001 compared to control groups, using ANOVA
followed by the Bonferroni post-hoc test.
Table 1
IC50 values for the chalcones and Taxol in relation to K562 and Jurkat cell lines after
incubation for 24 h.
Compounds IC50 values
K562 Jurkat
A1 40.13  1.04* 20.98  2.39*
A23 67.63  1.68 61.69  1.20
C24 71.74  2.09 59.46  1.28
Taxol 9.06  1.17 8.23  1.12
*p < 0.001 compared to control groups, using ANOVA followed by the Bonferroni
post-hoc test.
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For the screening, K562 and Jurkat cells were cultured at
a density of 1 105 and 2  105, respectively, in 96-well plates and
incubated with the chalcones C24, A23 and A1 dissolved in DMSO
for 24 h at different concentrations (1e100 mM). The selected
compound (A1) was incubatedwith the six leukemia cells lines (105
in 96-well) and with HT-29 and JMA cells (5104 in 96-well) at the
concentrations of 1, 5, 10, 25 and 50 mM for 24, 48 and 72 h. A
maximum volume of 20 ml of the test compounds were added to
cells and the same volume of the solvent was added to control
wells. Cell viability was assessed using MTT (3-(4, 5-dimethiazol-
zyl)-2-5-diphenyltetrazolium bromide, Sigma Chemical Co., St.
Louis, MO, USA) assay [33]. Taxol was used as a positive control.
2.5. Cell cycle analysis
To assess cell cycle arrest, a PI/RNase solution kit (Immunostep,
Salamanca, Spain) was used. Leukemia cells (1  106 cells/well)
were incubated with chalcone A1 at the half maximal inhibitory
concentration (IC50) for 12 h. Cells were harvested and cell cycle
analysis was carried out according to the kit protocol. Brieﬂy, cells
werewashedwith phosphate-buffered saline (PBS) and centrifuged
for 5 min at 1500 rpm. The supernatant was removed and the cells
were ﬁxed with 70% ethanol for 30 min at 4 C and washed with
PBS supplemented with 2% bovine albumin. The cell pellet was
resuspended in 500 ml buffer containing propidium iodide and
RNAse and stained for 15 min at room temperature. Analysis was
performed using BD FACSCanto II (Becton Dickinson Immunocy-
tometry Systems, USA) and analyzed by WinMID software.
2.6. Evaluation of apoptosis
Apoptotic cells were evaluated by morphological observation
with ethidium bromide and acridine orange, by ﬂow cytometry
with the Annexin V-FITC Apoptosis Detection kit and by the DNA
fragmentation assay.
For the morphological observation, cells treated with chalcone
A1 (1  106 cells/well, IC50) were stained with a solution of EB/AO
(1:1) at 1% concentration and observed under a ﬂuorescence
microscope (Olympus BX41) [34]. Representative ﬁelds were pho-
tographed with a digital camera.
To identify phosphatidylserine externalization during theprocess
of apoptosis, an Annexin V-FITC Apoptosis Detection kit was used
according to the manufacturer’s instructions. Brieﬂy, 1  106 cellswere incubated with chalcone A1 (at IC50). After 12 h, cells were
washed with PBS buffer and stained with Annexin V-FITC solution.
After incubation, Annexin buffer was added and ﬂuorescence was
analyzed by ﬂow cytometry. The analysis was performed on a BD
FACSCanto II (Becton Dickinson Immunocytometry Systems, USA)
ﬂow cytometer and data were analyzed by WinMID software [35].
For the DNA fragmentation assay, cells treated with chalcone A1
(1  106 cells/well, IC50) were washed with PBS and harvested by
centrifugation. Lysed cells were suspended in PBS solution and
10 mL of RNase A (20 mg/mL, SigmaeAldrich) was then added. After
incubation at 37 C for 45 min, the genomic DNA mini preparation
kit with a spin column was used to obtain the genomic DNA. The
genomic DNA was separated on a 2% agarose gel with 1 mg/mL
ethidium bromide for 50 min at 80 V [36].
2.7. Statistical analysis
Data are presented as the mean  standard deviation of at least
three experiments. Two-wayANOVAfollowedby theBonferroni post-
hoc test was used to compare the cytotoxicity of the compounds at
different times and concentrations, and the 2-tailed unpaired Student
t-test was used for Annexin V-FITC and cell cycle analysis. Statistical
analysis was carried out using the Statistical Package for Social
Sciences forWindows (SPSS Inc. version 13.0, Chicago, Illinois, USA).
The statistical signiﬁcance level was set at p < 0.05 for all analysis.
3. Results
3.1. Synthetic chalcones induced cytotoxicity in acute leukemia cell
lines
The effect of three synthetic chalcones (C24, A23 and A1) on the
viability of K562 and Jurkat cells was examined by MTT assay [33].
Fig. 3. Cytotoxicity of chalcone A1 against acute leukemia cell lines. Cells (1 105 cells/well) were incubated with chalcone A1 (1e50 mM) for 24, 48 and 72 h. The cell viability was
monitored through MTT assay. Optical density of control groups was taken as 100% of cell viability. Cell viability was checked at the beginning of the experiment by Trypan blue
exclusion. The results are the mean  SD of at least 3 independent experiments. *p < 0.001 compared to control groups, using ANOVA followed by the Bonferroni post-hoc test.
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trations (1, 5, 10, 25, 50 and 100 mM) for 24 h. As shown in Fig. 2(a)
and (b), all three chalcones signiﬁcantly reduced the cell viability in
a concentration-dependent manner when compared with the
control group (non-treated cells). The IC50 values of the three
compounds are shown in Table 1.
Among the evaluated compounds, chalcone A1 presented
the best results, with IC50 values of 40.13  1.04 mM and
20.98  2.39 mM for K562 and Jurkat cells, respectively. In addition,
when the compounds were compared in terms of the cytotoxicity
of each concentration, chalcone A1was signiﬁcantlymore cytotoxic
than chalcones C24 and A23 at the concentrations of 50 and 100 mM
in K562 cells, and at the concentrations of 10 and 25 mM in Jurkat
cells (data not shown). The difference between the other two
compounds was not statistically signiﬁcant. Therefore chalcone A1
was chosen for further assays.
3.2. Chalcone A1 reduced the cell viability in a concentration and
time-dependent manner in acute leukemia cell lines
As chalcone A1 was the most cytotoxic of the three assayed
compounds, it was selected for assay in six acute leukemia cell lines
for 24, 48 and 72 h, in order to evaluate its effect on different kinds
of human leukemias. As shown in Fig. 3, chalcone A1 signiﬁcantly
reduced the cell viability in a concentration and time-dependent
manner when compared with the control group (non-treatedTable 2
IC50 values for chalcone A1 in relation to K562, Jurkat, U937, Kasumi, NB4 and CEM cell
Time/cells K562 Jurkat U937
24 h 40.13  1.04 20.98  2.39 17.62 
48 h 17.87  0.66 5.49  1.75 10.33 
72 h 4.55  0.35 2.86  0.58 6.28 cells). The IC50 values for the three compounds are shown in
Table 2.
3.3. Chalcone A1 reduced the cell viability in a concentration and
time-dependent manner in human colon adenocarcinoma cells
In order to evaluate the inﬂuence of chalcone A1 in solid tumors,
the selected compound was tested in HT-29 cell line as a model of
a non-hematological cancer. As shown in Fig. 4, chalcone A1
signiﬁcantly reduced the cell viability in a concentration and time-
dependent manner, although the IC50 values were relatively higher
when compared to the leukemia cell lines. The IC50 values are
50.42  1.70 mM for 24 h, 23.10  1.36 mM for 48 h and
16.31  1.12 mM for 72 h.
3.4. Chalcone A1 is relatively non-cytotoxic to normal cells
To examine the cytotoxic effect of chalcone A1 on normal cells,
peripheral blood lymphocytes (PBL) collected from ﬁve healthy
non-smoker volunteers were incubated with 50 mM of the
compound for 24 h. The concentration was deﬁned as a higher
concentration than the highest IC50 found (40.13  1.04 mM). As
shown in Fig. 5(a), chalcone A1 is non-cytotoxic to PBL cells, with
a cell viability of 99.89  10.69%, while Taxol 30 mM conferred a cell
viability of only 14.55  7.91%. To further evaluate the speciﬁcity of
the compound to cancer cells, chalcone A1 was incubated withlines.
Kasumi NB4 CEM
0.70 7.72  0.60 3.58  0.31 5.33  0.81
0.68 4.67  0.34 1.48  0.44 2.82  0.68
0.65 2.53  0.42 1.90  0.46 1.85  0.49
Fig. 4. Cytotoxicity of chalcone A1 against HT-29 cells. Cells (5  104 cells/well) were
incubated with chalcone A1 (1e50 mM) for 24, 48 and 72 h. The cell viability was
monitored through MTT assay. Optical density of control groups was taken as 100% of
cell viability. Cell viability was checked at the beginning of the experiment by Trypan
blue exclusion. The results are the mean  SD of at least 3 independent experiments.
*p < 0.001 compared to control groups, using ANOVA followed by the Bonferroni post-
hoc test.
M.F. Maioral et al. / Biochimie 95 (2013) 866e874870human ﬁbroblasts cultured from bone marrow for 24 and 48 h. As
shown in Fig. 5(b), the compound did not reduce signiﬁcantly the
cell viability of JMA cells neither in 24 h nor in 48 h.
3.5. Cell cycle arrest provoked by chalcone A1
The effect of chalcone A1 on the cell cycle progression of K562,
Jurkat, U937, Kasumi, NB4 and CEM cells was evaluated at the
respective IC50 after 12 h of incubation. The assay was performed by
DNA content analysis through ﬂow cytometry. The data given in
Table 3 were obtained through separation of the cell cycle phases
by setting adjacent cursors without deconvolution of overlapping
G0/G1, S and G2/M phases. In comparison with the control group
(without treatment), treated cells showed a signiﬁcant increase in
the proportion of cells in the sub G0/G1 phase, suggesting an
increase in the apoptosis rate. The compound caused cell cycle
arrest in all six cell lines, reﬂected by a signiﬁcant increase in the
percentage of cells in the phase in which the cell cycle blocking
occurred. Chalcone A1 caused blocking in the G2/M phase in K562,
Kasumi and NB4 cells (32.83  1.17, 18.10  0.47 and 39.94  1.87,Fig. 5. Effect of chalcone A1 on normal cells. (a) Human peripheral blood lymphocytes (5 
viabilities were determined by MTT assay. (b) JMA human bone marrow ﬁbroblasts (5  10
viability was monitored through MTT assay. *p < 0.001 compared to control group, using trespectively), the S phase in Jurkat Cells (43.88  0.30) and the G0/
G1 phase in U937 and CEM cells (60.94  0.35 and 44.12  2.91,
respectively) (Table 3).
3.6. Chalcone A1 induced apoptosis in acute leukemia cell lines
To evaluate whether chalcone A1 induced cell death via an
apoptotic or necrotic pathway, the abnormalities of the cell
morphology were examined using ﬂuorescence microscopy. Viable
cells exhibited a green ﬂuorescence (acridine orange staining)
whereas apoptotic cells exhibited an orange-red nuclear ﬂuores-
cence (ethidium bromide staining) by intercalation of ethidium
bromide into damaged DNA in apoptotic cells. Cells treated with
chalcone A1 at IC50 for 12 h demonstrated the morphological
characteristic of apoptosis, such as chromatin condensation and
formation of apoptotic bodies (Fig. 6).
Apoptosis induced by chalcone A1 was conﬁrmed by exter-
nalization of phosphatidylserine, which is detected by the Annexin
V-FITC method [28]. As shown in Fig. 7(a), chalcone A1, after 12 h
of incubation, induces cell death via an apoptosis pathway,
showing a signiﬁcant increase in the percentage of Annexin V
positive cells when compared with the control group. To further
investigate the mode of cell death induced by chalcone A1, Jurkat
cells were submitted to DNA fragmentation assay. As shown in
Fig. 7(b), chalcone A1 induced marked DNA fragmentation in
Jurkat cells.
All these results conﬁrm that the percentage of leukemia cells
observed in the sub G0/G1 phase (Table 3) are undergoing
apoptosis, indicating that chalcone A1 induced apoptotic death of
human acute leukemia cell lines.
4. Discussion
Based on our previous report on the cytotoxic effects of chal-
cones derived from 2-naphthaldehyde on L-1210 cells [25], in this
study we synthesized three structurally modiﬁed chalcones (C24,
A23 and A1), in order to try to potentiate its effects. In comparison
with the structures of our previous study [25], we inserted a 3,4,5-
trimethoxy substitution at the A ring of 2-naphthyl-chalcone to
obtain compound C24, due to the previously described antileu-
kemic activity of 3,4,5-trimethoxy chalcone derivatives [37,38].
To better compare the potency and study the inﬂuence of the
naphthyl B-ring on the antileukemic activity, we also substituted
the 2-naphthyl moiety with the 1-naphthyl moiety in the chalcones
A23 and A1.105 cells/well) were incubated with chalcone A1 (50 mM) or Taxol (30 mM) for 24 h. Cell
4 cells/well) were incubated with chalcone A1 (1e50 mM) for 24, 48 and 72 h. The cell
test.
Table 3
Effect of chalcone A1 (IC50) on the cell cycle of acute leukemia cell lines.
Cell G0/G1 (%) S (%) G2/M (%) Sub G0/G1% (apoptosis%)
K562 Control 39.32  0.01 36.19  1.68 24.49  1.70 6.32  0.49
A1 30.66  2.95** 36.52  1.79 32.83  1.17** 12.04  0.05*
Jurkat Control 55.46  3.91 27.96  1.72 14.46  0.78 3.98  0.33
A1 33.52  6.29** 43.88  0.30* 22.50  5.98 44.06  7.45***
U937 Control 45.66  1.46 33.47  1.26 20.86  0.20 2.77  0.24
A1 60.94  0.35*** 22.10  2.26*** 16.96  2.61 18.98  0.60***
Kasumi Control 71.65  2.16 18.33  1.05 10.52  0. 41 9.34  0.33
A1 60.62  1.54*** 20.80  1.73 18.10  0.47** 16.19  1.06**
NB4 Control 56.66  0.42 25.39  1.00 17.95  0.58 16.99  1.28
A1 31.68  0.30*** 28.38  2.17 39.94  1.87*** 24.02  2.77**
CEM Control 34.82  2.02 40.37  1.46 24.82  3.48 13.63  0.47
A1 44.12  2.91** 33.85  0.98* 21.54  1.22 15.60  0.54
*p < 0.05, **p < 0.01, ***p < 0.001 compared to control groups, using ANOVA followed by the Bonferroni post-hoc test.
Fig. 6. Induction of apoptosis by chalcone A1 in acute leukemia cell lines. Morpho-
logical analysis after staining with EB/AO. Acute leukemia cells K562, Jurkat, U937,
Kasumi, NB4 and CEM were incubated (5  105 cells/well for 12 h) with chalcone A1
(IC50) and stained with a solution of EB/AO. Cells were observed under a ﬂuorescence
microscope (Olympus BX41) and representative ﬁelds were photographed with
a digital camera. Bar means 10 mm: magniﬁcation: 400. The group without the
compound was taken as the control group. Results were obtained from two separate
experiments.
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leukemia cell lines K562 and Jurkat in a concentration-dependent
manner, but surprisingly, compound A1 (2,5-dimetoxylated at
A-ring) showed the best results, in contrast to the ﬁndings of other
studies (where the 3,4,5-trimetoxy-chalcones generally provided
the best results) [37,38]. A1 was thus chosen for further analysis.
In comparisonwith the control drug Taxol (IC50 of 9.06 1.17 for
K562 and 8.23  1.12 for Jurkat cells) the cytotoxic results of A1 do
not seem to be very signiﬁcant. However, even though compound
A1 is not as cytotoxic as Taxol, it did not induce cell death in the
normal PBL (99.89  10.69%), while Taxol 30 mM gave a cellular
viability of only 14.55 7.91%, and this possible selectivity of A1 for
tumor cells is a positive point, despite the difference in cytotoxicity.
In addition, chalcone A1 did not reduce the cell viability of JMA cells
in 24 and 48 h of incubation. JMA cells are a normal human ﬁbro-
blasts cell line cultured frombonemarrow, chosen to be testedwith
the compound for being probably themost similar model of normal
cells to leukemia lines. The evaluation with the ﬁbroblasts
conﬁrmed the results obtained with the normal PBL, suggesting
a speciﬁcity of the compound to neoplastic cells. Non-cytotoxicity
toward healthy cells suggests a possible decrease in the adverse
effects, which are often related to patient morbidity and mortality
[39], and are common in conventional treatments for acute
leukemia’s using compounds with potent IC50 values.
Compound A1 also demonstrated a time-dependent cytotox-
icity in six human acute leukemia cell lines. In the assays, 50 mM of
compound was chosen as the maximal concentration because
higher doses do not normally reach the blood plasma [40,41]. In
addition, we are looking for compounds with potential activity,
which could be used in the future as prototypes to direct the
synthesis of new drugs for cancer chemotherapy, with very little or
no adverse effects.
The cytotoxic effect of chalcones has been previously evaluated
in other studies and IC50 values between 0.0043 mM and 30 mM
were found in the case of K562 cells (2  103 cells/ml) incubated
with the compounds for 5 days [37,38,42]. Jurkat cells (2106 cells/
ml) treated with chalcones had IC50 values between 1.7 mM and
66 mM after 24 h of incubation [30]. The evaluation of amino-
chalcones against CEM cells revealed IC50 values lower than 10 mM
[43], and chalcone derivatives tested on U937 cells showed potent
cytotoxicity in a dose-dependent manner [44]. However, despite all
of these studies having been reported, previous assays with chal-
cones in NB4 or Kasumi cells were not found.
The difference in the IC50 values for the different cell types can
be explained by the particularities of each subtype of acute
leukemia cells. For example, K562 is a kind of chronic myeloid
leukemia that occurs in blastic myeloid transformation (blastic
phase) and which tends to be more aggressive and treatment-
resistant than other kinds of leukemia [45].
Fig. 7. Induction of apoptosis by chalcone A1 in acute leukemia cell lines. (a) Induction of apoptosis by chalcone A1 in acute leukemia cells by Annexin V-FITC method. Cells were
treated for 12 h in the absence and presence of compound A1 (IC50). The apoptosis was determined by tagging cells with Annexin V-FITC and analysis by ﬂow cytometry. These
graphs represent two independent experiments. (b) DNA fragmentation analysis of Jurkat cells. The level of DNA fragmentation was determined using the genomic DNA mini
preparation kit with a spin column to obtain the genomic DNA. This was then separated in 2% agarose gel with 1 mg/mL ethidium bromide for 50 min at 80 V.
M.F. Maioral et al. / Biochimie 95 (2013) 866e874872It is very important to note that in the present study chalcone A1
presented a strong cytotoxic activity mainly in Kasumi, NB4 and
CEM cells after 72 h of treatment, with IC50 values of 2.53  0.42,
1.90 0.46 and 1.85 0.49, respectively (Table 2), indicating the A1
is potentially a new candidate lead compound for the development
of antitumor agents.
In order to evaluate the capacity of chalcone A1 to induce cell
death in non-hematological cells, we tested the compound in
human colon adenocarcinoma cells HT-29. Despite the aim of this
study was to evaluate the cytotoxicity of synthetic chalcones on
the leukemia model, we showed that the compound was also
cytotoxic to this solid tumor cell line. Even though de IC50 values
were higher than the leukemia ones, cell death was signiﬁcant at
25 and 50 mM. The cytotoxic effect of chalcones has been previ-
ously evaluated in solid tumors, mainly lung cancer, colon
adenocarcinoma, hepatocellular carcinoma and prostate adeno-
carcinoma. Signiﬁcant cytotoxic results were found for all the cell
types and the IC50 for HT-29 cells were 94.10  1.19 mM, higher
than chalcone A1 [46e48].
Cells have multiple mechanisms of cell cycle checks to monitor
and respond to cellular disturbances. They can prevent the
progression of altered cells until the errors are repaired or until the
promotion of apoptosis by p53 protein. Disturbances related to
these responses compromise the integrity of the genome and
promote the development of cancer, signiﬁcantly affecting the
efﬁcacy of antitumor therapies. Since the effects of compounds on
the cell cycle play an important role in the development of effective
therapies against cancer [49e51], we investigated the effect of
compound A1 on cell cycle progression in the six human acute
leukemia cell lines. Chalcone A1 increased the proportion of cells in
the sub-Go/G1 phase (apoptosis). It also blocked the cell cycle in all
six cell lines analyzed: in the G2/M phase in K562, Kasumi and NB4cells, in the S phase in Jurkat cells and in the G0/G1 phase in U937
cells. The blocking in different stages can be explained by the
speciﬁc characteristics of the different types of leukemia.
Several studies have shown that the antiproliferative activity of
chalcones is due to their interference with different cell cycle
phases. Some chalcones may bind to tubulin, preventing poly-
merization of the microtubule and therefore causing blocking in
the G2eMphase of the cell cycle of K562 and Jurkat cells [27,28,52].
This information is in agreement with our results for K562, Kasumi
and NB4 cells. A slight but not signiﬁcant blocking in the G2/M
phase was also observed in Jurkat cells. Other studies have shown
blocking in the G0/G1 phase of Jurkat and U937 cells treated with
chalcone derivatives [29,30] and we obtained the same results for
U937 and CEM cells. These ﬁndings suggest that the chalcones
might cause cell death by different mechanisms according to the
acute leukemia subtype observed in leukemia cell lines.
To elucidate the death mechanism induced by compound A1 in
K562, Jurkat, Kasumi, U937, NB4 and CEM cells, we investigated
whether this compound could induce apoptosis by three different
methods: ethidium bromide and acridine orange, Annexin V-FITC
and DNA fragmentation.
Using the ethidium bromide and acridine orange methods cells
incubated with compound A1 showed an increased number of
apoptotic cells. The control group (non-treated cells) showed
a characteristic green color after staining with acridine orange and
nucleus integrity, indicating that the cells were viable. Cells treated
with compound A1 at IC50 presented the morphological charac-
teristic of apoptosis. Early apoptotic cells still have an intact
membrane and were identiﬁed as green cells with chromatin
condensation and nuclear fragmentation. Late apoptotic cells lost
their membrane integrity and were stained by ethidium bromide
with an orange color.
M.F. Maioral et al. / Biochimie 95 (2013) 866e874 873Apoptosis was conﬁrmed by externalization of phosphati-
dylserine residues, which bind to Annexin V. Chalcone A1 showed
a signiﬁcant increase in the percentage of Annexin V-positive cells
when compared to the control group. A1 could also induce DNA
fragmentation in Jurkat cells. We found other studies in the liter-
ature showing that chalcones induce cell death via apoptotic
pathways. Ye et al. (2005) reported that a natural chalcone, isolated
from the buds of Cleistocalyx operculatus, provoked apoptosis in
K562 cells by down-regulating of the antiapoptotic protein Bcl-2
[22]. Similar results were found for K562 cells treated with
a synthetic chalcone which induced apoptosis through the mito-
chondrial pathway and activated caspase-3 [26]. Synthetic chal-
cones also caused apoptosis in Jurkat cells by reducing the
expression of the anti-apoptotic gene, Bcl-2, and increasing the
expression of the pro-apoptotic gene, Bax [27]. No studies were
found in the literature in relation to the other cell lines.
Our results conﬁrmed that the cells observed in the sub G0/G1
phase are undergoing apoptosis and are compatible with the
results obtained in the assessment of cell viability by MTT.
These combined in vitro effects suggest that chalcone A1 is
a compound with bioactive potential that might be used as a lead
compound for the development of antileukemic drugs. Further
assays need to be carried out in order to elucidate the apoptotic
pathways by which this compound causes cell death.
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